Cite
HARVARD Citation
Gane, E. et al. (2016). Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1 infection. Journal of viral hepatitis. 23 (10), pp. 789-797. [Online].